Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …

Background. Tacrolimus pharmacokinetic characteristics vary greatly among individuals.
Tacrolimus is a substrate of cytochrome P450 (CYP), of subfamily CYP3A. CYP3A activity is …

Previously, we reported that, at 3 months after renal transplantation, individuals with
CYP3AP1 genotype CYP3AP1* 1 (linked to CYP3A5* 1 and strongly associated with …

Results EM had an 88% lower dose-adjusted C 0 compared with IM. PM had a 26% higher
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …

Pretransplantation adaptation of the daily dose of tacrolimus to CYP3A5 genotype is
associated with improved achievement of target trough concentration (C 0), but whether this …

Objectives: The aims of this study were to develop a population pharmacokinetic model of
tacrolimus in adult kidney transplant recipients, to use this model to compare cytochrome …

ABSTRACT Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has
considerable toxicity and inter-individual variability in pharmacokinetics and …

OBJECTIVE: Tacrolimus concentrations are associated with CYP3A5 genotype. The
purpose of this study was to evaluate the outcomes and drug concentrations/doses among a …

To prevent acute rejection episodes, it is important to reach adequate tacrolimus (TRL)
exposure early after kidney transplantation. With a better understanding of the high …

Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …